ty -jour a2 -taliani，gloria au-托马斯，惠特尼·艾（Whitney Au） - 阿尔巴诺（Albano），亚当·艾（Adam au） - 柯克尔（Adam au），迪恩·艾（Dean au -dean au -rohizad） - 鲁尼扎德（Rouhizad），nason au -arinze -arinze，folasade py -2021 da -2021/1021/10/09 ti-免疫动型purboctianic pervistra partistration in基于mRNA的SARS-COV-2和MMR疫苗接种：警告性故事SP-2704249 VL-2021 AB-我们报告了一例免疫血小板减少紫癜（ITP），在一名健康的31岁男子中，现场直播后有31岁的男子带有辉瑞-biontech mRNA SARS-COV-2疫苗的麻疹，腮腺炎和风疹（MMR）疫苗。该患者短暂住院并用糖皮质激素，IVIG和血小板输血治疗ITP。Although our patient’s clinical presentation and subsequent course are similar to those of other cases of ITP in association with SARS-CoV-2 vaccination, to our knowledge, this is the first reported case of ITP following MMR and mRNA SARS-CoV-2 vaccine coadministration. It would be impossible to conclusively prove that the patient’s thrombocytopenia was secondary to the SARS-CoV-2 vaccine alone, the MMR vaccine, or an additive effect of both vaccines. However, with the CDC guidelines recommending the coadministration of the mRNA SARS-CoV-2 vaccine without regards to timing with other vaccines, we urge further caution as there is limited evidence to inform practice. This case highlights the need for further safety data regarding the coadministration and timing of the mRNA SARS-CoV-2 vaccine with other vaccines. SN - 2090-6625 UR - https://doi.org/10.1155/2021/2704249 DO - 10.1155/2021/2704249 JF - Case Reports in Infectious Diseases PB - Hindawi KW - ER -